Results 91 to 100 of about 192,487 (273)

Adherance to approved protocol chemotherapy for breast cancer at Songklanagarind Hospital

Journal of Health Science and Medical Research (JHSMR), 2002
At Songklanagarind Hospital, a protocol for chemotherapy in breast cancer has been used since 1994. The purpose of this study was to examine "non-medical" factors that may reflect non-acceptance of this protocol.
W Achanond, K Tangkietgumjai, T Ovartlarnporn, J Prukpitikul, A Naulsri, W Leelasamran, D Supawatanawong, U Wongsatit   +7 more
doaj  

Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report. [PDF]

, 2015
Regorafenib, an oral multikinase inhibitor, was approved in September 2012 by the US Food and Drug Administration for the treatment of patients with metastatic colorectal cancer.
Herman, June, Kain, Tatiana, Seery, Tara, Tang, Ronald   +3 more
core   +3 more sources

Context‐Dependent Role of GDF15: GDF15+ Tumor‐Associated Macrophages Suppress OSCC Progression by Enhancing Phagocytosis

Advanced Science, EarlyView.
This study identifies GDF15+ TAMs as a cell subset mediating tumor regression after immunotherapy. Macrophage‐intrinsic GDF15 enhances phagocytosis and antigen cross‐presentation to CD8+ T cells through the NF‐κB signaling pathway, thereby inhibiting tumor progression.
Xinyu Zhou, Zhihang Zhou, Houyu Ju, Chaoyang Guo, Fangxing Zhu, Yiyi Zhang, Xu Chen, Tongchao Zhao, Laiping Zhong, Jingzhou Hu   +9 more
wiley   +1 more source

Role of gemcitabine in the treatment of advanced and metastatic breast cancer [PDF]

, 2003
Gemcitabine is an antimetabolite drug with proven antitumor activity and tolerability in metastatic breast cancer. In a total of nine studies, gemcitabine monotherapy has reached response rates of up to 37% in the first-line setting, 26% in the second ...
Heinemann, Volker
core   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

SMAD4 Palmitoylation Drives a Metabolic‐Transcriptional Circuit to Promote Tumorigenesis and Confers Radiosensitivity in Pancreatic Cancer

Advanced Science, EarlyView.
This study identifies palmitoylation as a novel regulatory modification of SMAD4, mediated by ZDHHC22/APT2. It activates fatty acid synthesis, creating a self‐reinforcing SMAD4–FASN–palmitate feedback loop that drives pancreatic cancer growth and enhances radiotherapy sensitivity.
Yang Wang, Shan Zhang, Junping Bai, Xiaobing Li, Yi Han, Min Ji, Chongyi Jiang, Xiaobei Ge, Tianyu Yu, Yongying Hou, Jun Zhang, Wangting Li, Yiran Song, Jiaying Cai, Yingqun Zhou, Liwei An, Feng Wang   +16 more
wiley   +1 more source

Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy [PDF]

, 2013
Uracil in DNA is an important cause of mutagenesis. SMUG1 is a uracil DNA glycosylase that removes uracil through base excision repair. SMUG1 also processes radiation induced oxidative base damage as well as 5-fluorouracil incorporated into DNA during
Abdel-Fatah, TMA, Agarwal, D, Albarakati, N, Ball, G, Bowell, L, Chan, S, Ellis, IO, Hawkes, C, Madhusudan, S, Moseley, P   +9 more
core   +1 more source

Loss of VMP1 Impairs Tight Junction Recycling and Aggravates Intestinal Barrier Dysfunction in Inflammatory Bowel Disease

Advanced Science, EarlyView.
This study identifies vacuole membrane protein 1 (VMP1) as a critical regulator of intestinal epithelial barrier homeostasis. VMP1 facilitates the recruitment of CORO1C to late endosomes, supporting Retromer‐mediated recycling of the tight junction protein Occludin.
Jiawei Zhao, Jianjun Zou, Chen Zhou, Yingui Wang, Yiman Liu, Yanqing Zhou, Yuxiang Wang, Xinyu Zhang, Huishu Yang, Hongjie Yin, Dongsheng Bai, Yue Zhao, Na Lu   +12 more
wiley   +1 more source

Experimental Study Evaluating the Effect of Combined Methotrexate and Fluorouracil Therapy on Anemia in Mice With L1210 Lymphoid Leukemia

Pteridines, 1997
Combined methotrexate (MTX) and fluorouracil (FU) has heen used for many years to treat neoplastic diseases. However, clinical and laboratory snldies are still carried out to explain the changes that the therapeutic and toxic effects undergo when MTX and
Graczyk Julita
doaj   +1 more source

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

Advanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu, Mengtao Sun, Lusheng Li, Jieqiong Wang, Shibiao Wan   +4 more
wiley   +1 more source